TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01625806

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RO4602522
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4602522
Description: Single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Multiple oral doses
Study: NCT02814773

Intervention type: OTHER
Intervention: questionnaires
Study: NCT04824716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postconditioning
Description: The protocol of primary PCI followed by stenting is executed according to the descriptions according to the majority of relevant scientific literature on postconditioning studies and in accordance with the most recent guidelines. In the post conditioned group, after recanalization, the artery is occluded by inflation of stent balloon (4 times for 1-1 minute) followed by 1-1-minute reperfusion, repeatedly. Eight minutes after the start of examination, angiography is made in order to determine blood flow. Intervention is finished by the operator and another angiographic image is made (identical to initial standard projection).

Intervention type: DEVICE
Group type: OTHER
Intervention: Percutaneous coronary intervention
Description: Percutaneous coronary intervention as per European Society of Cardiology guidelines.
Study: NCT01986777

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lisdexamfetamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo capsules will be filled with lactose.
Study: NCT03389685

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma
Description: Pure PRPII®, leukocyte-poor, platelet rich plasma

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline Placebo
Description: saline solution
Study: NCT03246425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator mode change
Description: The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator mode change
Description: The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
Study: NCT01864356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT100

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00674154

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cholecalciferol
Description: 2800 IE daily in 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol
Description: 2800 IE daily in 52 weeks
Study: NCT04261543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High protein and early exercise
Description: High protein is defined as protein prescription of ≥2.2 gram/kg body weight and early exercise is defined as starting cycle ergometry intervention within 24 hours of randomization

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care group has protein prescription of ≤1.2 gram/kg body weight and exercise at the discretion of attending clinicians
Study: NCT04650061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview (MI) & Adherence Follow-Up
Description: With MI, the key goal is to empower the patient to commit to follow CPAP therapy, while providing empathic support, in a positive atmosphere, and without prejudice. The nurse does not directly advocate for behavior change (i.e. use CPAP as prescribed), but asks key questions to help the patient explore their feelings about the change, weighs the pros and cons of such change, and allows the patient to realize the discrepancy between the current risk (that is, not using CPAP as directed) and the benefits with good adherence.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Adherence Follow-Up
Description: The nurse takes the compliance of the CPAP device, and ask to the patient if he had some problems.
Study: NCT01716871

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neurocryostimulation with Duo-cryo® device
Description: organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cryotherapy with Cold pack® or ice-cubes pack
Description: Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.~The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group.
Study: NCT03553030

Intervention type: DEVICE
Intervention: coronary artery angiography
Description: In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.

Intervention type: DEVICE
Intervention: coronary artery angiography
Description: In all patients authors performed a coronary artery angiography for detection of coronary artery stenosis.
Study: NCT03246425

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ventilator mode change
Description: The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
Study: NCT01278654

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive to exercise
Description: Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Incentive to exercise
Description: Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
Study: NCT03246425

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Monitoring of blood pressure variation
Description: The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
Study: NCT04490889

Intervention type: DIAGNOSTIC_TEST
Intervention: NiPGT-A
Description: NiPGT-A is the technique to screen the aneuploidy status of an embryo without invasion technique, such as biopsy. We use SCM to isolate cfDNA, then amplify and analyse the aneuploidy of embryo secreting this material using NGS technique.
Study: NCT00673595

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.~The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
Study: NCT03102190

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Hydrochloride Intranasal
Description: Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
Study: NCT02985931

Intervention type: OTHER
Intervention: Diagnostic imaging scans of SPECT and MRI
Study: NCT01609478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo delivered via Concept 1 inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: via Twisthaler inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate
Description: via Twisthaler inhaler

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mometasone furoate
Description: via Twisthaler inhaler
Study: NCT00643240

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: yttrium Y 90 anti-CD19 monoclonal antibody BU12
Description: Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 111In-BU-12
Description: Patients receive indium-111 BU-12 IV over 60 minutes on day 0
Study: NCT04919915

Intervention type: DEVICE
Group type: OTHER
Intervention: HEPA air cleaner
Description: Participants in the intervention group received two HEPA air cleaners per household. They were informed to place the HEPA air cleaners in the child's bedroom and the living room. Field staff provided and discuss how to use the air cleaner which promoted continuous operation of both air cleaners, keeping the child's bedroom door closed, and selected the highest fan speed. Typical use of the HEPA cleaners were questioned during the mid-study and final visits.
Study: NCT03173703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant the XenoSure patch
Description: The LeMaitre XenoSure patch will be used when close the repaired vessel

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair/reconstruction of the diseased vessel
Description: The diseased vessel is surgically repaired such as removing the clots.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair/reconstruction of the diseased vessel
Description: The diseased vessel is surgically repaired such as removing the clots.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implant the Vascular-Patch
Description: The B. Braun Vascular-Patch will be used when close the repaired vessel
Study: NCT03569267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLX10010
Description: A cell penetrating asymmetric siRNA (cp asiRNA)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02978222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FRα peptide plus Adjuvant (GM-CSF)
Description: Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adjuvant (GM-CSF) Alone
Description: Intradermal injection 125 μg GM-CSF
Study: NCT04713943

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: >Your< Iron Syrup
Description: Once daily dose of \>Your\< Iron Syrup in the amount of 1 mg/kg body weight of elemental iron for 12 weeks

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Description: Once daily dose of placebo syrup for 12 weeks
Study: NCT03476044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 40 patients will receive starch capsules orally with sips of water 2 hours before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Selenium
Description: 40 patients will receive Selenium (selenium NATURE'S BOUNTY, INC. Bohemia) 200 mcg orally with sips of water 2 hours before induction of general anesthesia
Study: NCT02351362

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Incentive Group
Description: A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
Study: NCT03711383

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin and Resistant Starch
Description: 12g per inulin in combination 7.5 g resistant starch per day the day before the CID Resistant starch 7.5 g

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin
Description: 12g per inulin in combination with maltodextrin per day the day before the CID

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: isocaloric maltodextrin before test day
Study: NCT01588223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lipid identification
Description: The lipids are identified using Mass Spectrometry
Study: NCT05859087

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Bedside pregnancy intention screening and family planning counseling with offer of bedside contraception initiation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flyer
Description: Handing flyer to patient that discusses the importance of talking with their doctor about pregnancy intention and contraception use.
Study: NCT02938182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: clopidogrel troche 75 mg daily for three months
Study: NCT02601417

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ignoring result of bile culture
Description: the antibiotic therapy was modified based only on the blood culture findings, where the blood cultures revealed insensitive organisms with the resistance to empirical antibiotics. The bile specimens from these patients were also obtained and cultured, but their results were not considered in the decision-making for antibiotic selection in the experimental group
Study: NCT03932526

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine + placebo
Description: Combined administration of vinorelbine and placebo. Based on oral administration of vinorelbine, the patients will be given oral placebo (starch as an ingredient). The placebo appearance, including shape, size, color and weight, taste, labeling and packing are the same with those of apatinib mesylate tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine + Apatinib
Description: Combined administration of vinorelbine and apatinib. Vinorelbine tartrate soft capsule (also named Navelbine; registration No. H20140657; Pierre Fabre Medicament, Boulogne, France) 40 mg once orally, taken in the morning (at least 1 hour before or at least 1 hour after meals), three times a week (Mondays, Wednesdays, and Fridays), for a continuous 21-day cycle. Apatinib mesylate tablets (also named Aitan, State Medical Permission No. H20140103; Jiangsu Hengrui Pharmaceutical Co., Ltd., China), 500 mg orally, taken once a day for a continuous 21-day cycle.
Study: NCT04151108

Intervention type: OTHER
Intervention: Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers
Description: Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)

Intervention type: OTHER
Intervention: Development of a risk assessment tool based on clinical and functional measures and systemic biomarkers
Description: Blood tests, frailty (CSHA Clinical Frailty Scale) and risk of pressure ulcers (Braden Score), Early Warning Score (EWS), sarcopenia (SARC-F), malnutrition (SNAQ), cognitive status, comorbidity (Charlson comorbidity Index), polypharmacy, muscle strength, and body composition (BIA)
Study: NCT00924625

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Volitional exercises
Description: The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
Study: NCT00559182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK-8033
Description: MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at \~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).~Enrollment in Parts A and B has been completed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: MK-8033 +/- omeprazole
Description: Part C will occur at only one of the investigational sites.~In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.~Enrollment for Part C has been suspended.
Study: NCT00781352

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrous oxide
Description: 65% nitrous oxide administered during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nitrogen
Description: Nitrogen administration during surgery
Study: NCT02829541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB068
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB068
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB068
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB068
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB068
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB068
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT02963844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory Muscle Training

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Inspiratory Muscle Training Sham
Study: NCT04108351

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Road-tracking test
Description: Driving with simulator program for SDLP measurement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Car-following test
Description: Intervention Description: Driving with simulator program for DCV measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Car-following test
Description: Intervention Description: Driving with simulator program for DCV measurement

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Harsh-braking test
Description: Driving with simulator program for BRT measurement
Study: NCT01389063

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
Study: NCT01625195

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: omega-3 fatty acid supplementation
Description: This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4 x 1285 mg fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn/soybean oil placebo
Description: This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 4x 1285 mg capsules/d, two capsulesat breackfast and two capsules at dinner. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials.